Blood Reviews最新文献_第5页

Reinventing the wheel in ischemic stroke: Novel aspects in ADAMTS13 and von Willebrand axis 缺血性中风的车轮再造：ADAMTS13和von Willebrand轴的新方面。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-02-25 DOI: 10.1016/j.blre.2026.101365

Michail Makris , Paschalis Evangelidis , Nikolaos Devrikis , Pavlos Simonopoulos , Eleftheria Ztriva , Vasileios Patriarcheas , Vasiliki Gougoula , George Ntaios , Eleni Gavriilaki , Georgia Kaiafa

{"title":"Reinventing the wheel in ischemic stroke: Novel aspects in ADAMTS13 and von Willebrand axis","authors":"Michail Makris , Paschalis Evangelidis , Nikolaos Devrikis , Pavlos Simonopoulos , Eleftheria Ztriva , Vasileios Patriarcheas , Vasiliki Gougoula , George Ntaios , Eleni Gavriilaki , Georgia Kaiafa","doi":"10.1016/j.blre.2026.101365","DOIUrl":"10.1016/j.blre.2026.101365","url":null,"abstract":"<div><div>A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), is an enzyme that cleaves ultra-large von Willebrand factor (VWF) multimers. ADAMTS13 deficiency leads to thrombotic thrombocytopenic purpura (TTP), a thrombotic microangiopathy characterized by micro-thrombosis in small vessels and target-organ damage. Given that in long-term TTP survivors, reduced ADAMTS13 activity has been associated with the development of major cardiovascular events, the emerging evidence regarding the dysregulation of the ADAMTS13/ VWF axis in the pathogenesis of ischemic stroke (IS), and the unmet need for novel predictive models for IS outcomes and novel targeted therapeutics, we aim to review the current literature to provide an overview of the ongoing research on this field. Our objective is to summarize the evidence from experimental and clinical studies to underline the pathogenetic and therapeutic potential of VWF-ADAMTS13 in IS, while also providing perspectives for future research in this domain.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101365"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147319181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game ph染色体阴性骨髓增生性肿瘤：克隆动力学是游戏的名称。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-03-06 DOI: 10.1016/j.blre.2026.101385

Mohammadamin Noorafrooz , Ramin Noorafrooz , Giovanni Barosi , Robert Peter Gale

引用次数: 0

Autoimmune hemolytic anemia: New frontiers in diagnosis and therapy 自身免疫性溶血性贫血：诊断和治疗的新领域。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-03-06 DOI: 10.1016/j.blre.2026.101384

Wilma Barcellini , Bruno Fattizzo

引用次数: 0

Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies 在自身免疫性细胞减少症中实现免疫重置：来自B细胞消耗疗法临床经验的见解。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-03-12 DOI: 10.1016/j.blre.2026.101387

David J. Kuter , Sigbjørn Berentsen , Nichola Cooper , Lei Zhang , Jun Shi , Yunfei Chen , Lele Zhang , Charlie Zhou , Yanrong Wang , Jaideep S. Dudani , Neelufar Mozaffarian

{"title":"Towards achieving immune reset in autoimmune cytopenias: Insights from clinical experiences with B cell depleting therapies","authors":"David J. Kuter , Sigbjørn Berentsen , Nichola Cooper , Lei Zhang , Jun Shi , Yunfei Chen , Lele Zhang , Charlie Zhou , Yanrong Wang , Jaideep S. Dudani , Neelufar Mozaffarian","doi":"10.1016/j.blre.2026.101387","DOIUrl":"10.1016/j.blre.2026.101387","url":null,"abstract":"<div><div>Autoimmune cytopenias (AICs) arise from pathogenic autoantibody-mediated destruction of blood cells. Current treatments often fail to achieve durable remission, necessitating long-term treatment including immunosuppression and exposure to treatment-related toxicities. Insights into B cell biology demonstrate the central role of autoreactive B cells and plasma cells in sustaining disease activity and relapse, providing a rationale to achieve sustained, treatment-free remissions through “immune reset”.</div><div>This review summarizes the current understanding of immune reset in AICs and examines clinical data for depletion strategies targeting distinct stages of B cell maturation. We compare therapeutic modalities across monoclonal antibodies, bispecific T cell engagers (TCE), and chimeric antigen receptor (CAR) T cells. The depth and breadth of depletion, kinetics of immune reconstitution, and treatment-related risks are critical determinants of long-term outcome potential and individualized risk–benefit assessment. Collectively, these advances support a potential paradigm shift from chronic immunosuppression towards durable remissions off therapy with time-limited therapeutic interventions.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101387"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147482504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety 卡普拉珠单抗治疗免疫性血栓性血小板减少性紫癜的最新系统评价和荟萃分析：疗效和安全性的见解。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2025-12-20 DOI: 10.1016/j.blre.2025.101359

Mohamed Yassin , Rola Ghasoub , Neda Jafari , Lulwah Al-Tourah , Anas Babiker , Muna AlRasheed

{"title":"An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety","authors":"Mohamed Yassin , Rola Ghasoub , Neda Jafari , Lulwah Al-Tourah , Anas Babiker , Muna AlRasheed","doi":"10.1016/j.blre.2025.101359","DOIUrl":"10.1016/j.blre.2025.101359","url":null,"abstract":"<div><div>This review synthesizes the current evidence to assess the efficacy and safety of caplacizumab in the treatment of iTTP, focusing on its impact on TPE requirements, time to platelet normalization, relapse prevention, and treatment-related adverse events. Thirteen studies (11 observational and 2 RCTs), involving 2956 patients with iTTP were included. The majority of included studies were of high methodological quality, indicating a low risk of bias based on the assessment tools. The analysis found that caplacizumab was associated with significant clinical benefits. It marked a reduction in daily TPE sessions (MD = −3.92, <em>p</em> < 0.001) and time to platelet normalization (MD = −2.44, <em>p</em> = 0.03). Caplacizumab also significantly reduced mortality (RR = 0.29, <em>p</em> < 0.001) and iTTP exacerbations (RR = 0.27, p < 0.001), leading to shorter hospital stays (MD = −5.13, <em>p</em> = 0.001). Caplacizumab demonstrated notable clinical benefits in managing iTTP, with significant reductions in daily TPE sessions, time to platelet normalization, mortality, and iTTP exacerbations. Promising results were also noticed for early initiation compared to delayed initiation.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101359"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL 超越R-CHOP：抗体-药物偶联物在DLBCL中的崛起。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-01-31 DOI: 10.1016/j.blre.2026.101363

Xiaoxiao Xu , Meichen Liu , Zhenxing Wang

{"title":"Beyond R-CHOP: The rise of antibody-drug conjugates in DLBCL","authors":"Xiaoxiao Xu , Meichen Liu , Zhenxing Wang","doi":"10.1016/j.blre.2026.101363","DOIUrl":"10.1016/j.blre.2026.101363","url":null,"abstract":"<div><div>Diffuse large B-cell lymphoma (DLBCL) remains a therapeutic challenge, as a substantial proportion of patients experience relapsed or refractory (R/R) disease. Antibody-drug conjugates (ADCs) have emerged as a transformative class of targeted therapy, designed to deliver potent cytotoxic payloads directly to malignant cells via specific surface antigens. This approach enhances antitumor efficacy while minimizing toxicity. Recently, ADCs have expanded the DLBCL therapeutic landscape, with the approvals of CD79b-targeted polatuzumab vedotin and CD19-directed loncastuximab tesirine for R/R and even frontline disease. Additionally, numerous other ADCs targeting antigens such as CD22, CD30, and CD37 are under clinical investigation. However, the clinical application of ADCs is accompanied by challenges, including the management of characteristic toxicities, understanding and overcoming mechanisms of resistance. This review systematically synthesizes the mechanisms of action, updated clinical evidence, toxicity profiles, and resistance mechanisms of ADCs in DLBCL, while also discusses management strategies and provides perspectives on future directions.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101363"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting 重新审视抗磷脂综合征：一种凝血以外的血栓炎性疾病。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-02-21 DOI: 10.1016/j.blre.2026.101364

Catherine B. Ducker , Megan V Preece , Charis Pericleous , Mike Laffan , Deepa J. Arachchillage

{"title":"Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting","authors":"Catherine B. Ducker , Megan V Preece , Charis Pericleous , Mike Laffan , Deepa J. Arachchillage","doi":"10.1016/j.blre.2026.101364","DOIUrl":"10.1016/j.blre.2026.101364","url":null,"abstract":"<div><div>The dysregulation of protective immunothrombosis is termed thrombo-inflammation. Antiphospholipid syndrome (APS) is an antibody mediated autoimmune, inflammatory and prothrombotic disease. APS is an archetypal disease for thrombo-inflammation, in which a proinflammatory/prothrombotic state is caused by antiphospholipid antibodies (aPL). These antibodies directly or indirectly exert effects on monocytes and neutrophils, as well as platelets and endothelium, through binding of phospholipid binding proteins. In addition, aPL are linked with activation of coagulation and complement, leading to thrombosis. Although APS is an autoimmune antibody-mediated prothrombotic disease, its main treatment strategy at present is anticoagulation. Anticoagulation does not modulate endothelial cells or inflammation. This could explain the high risk of recurrent thrombosis, despite patients being on adequate anticoagulation. This review examines endothelial dysfunction and thrombo-inflammation in thrombotic APS as understanding the role of thrombo-inflammation in the pathogenesis of APS may help to develop new treatments or repurpose existing treatments.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101364"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147319176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bystander or perpetrator: Unravelling the significance and challenges of MGUS 旁观者或肇事者：揭示MGUS的意义和挑战。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-01-30 DOI: 10.1016/j.blre.2026.101362

Malini Surapaneni , Jacob Edmisson , Attaya Suvannasankha , Kelvin P. Lee , Ola Landgren , Rafat Abonour

{"title":"Bystander or perpetrator: Unravelling the significance and challenges of MGUS","authors":"Malini Surapaneni , Jacob Edmisson , Attaya Suvannasankha , Kelvin P. Lee , Ola Landgren , Rafat Abonour","doi":"10.1016/j.blre.2026.101362","DOIUrl":"10.1016/j.blre.2026.101362","url":null,"abstract":"<div><div>Monoclonal gammopathy of undetermined significance (MGUS) represents a premalignant clinical state with an evolving footprint beyond its established role as a precursor to multiple myeloma. This review is intended for hematologists, oncologists, and translational investigators involved in MGUS risk stratification and prevention research and confronts four unresolved controversies shaping modern MGUS management: (1) The debate surrounding population screening—weighing potential benefits against economic/psychological burdens; (2) Limitations of current risk-stratification models and the promise of dynamic genomic tools; (3) The contentious pathogenic role of MGUS in non-malignant conditions versus its frequent bystander status; and (4) The paradigm-shifting question of early intervention to prevent malignancy. We synthesize emerging evidence suggesting that while MGUS presents unique opportunities for myeloma prevention, significant knowledge gaps persist in risk prediction, disease biology, and therapeutic strategy. Future progress hinges on defining the right patient, right time, and right intervention through advanced biomarker discovery and carefully designed clinical trials.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101362"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146144830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia 报道不足和评价不足：解决慢性髓性白血病TKI耐受性文献的空白。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-02-26 DOI: 10.1016/j.blre.2026.101366

Dennis Dong Hwan Kim , Daniela Zackova , Massimo Breccia , Fabian Lang , Emiko Sakaida , Qian Jiang , Raquel De Paz , Bingcheng Liu , Susanne Isfort , David Yeung , Tomoiku Takaku , Tim H. Brümmendorf

{"title":"Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia","authors":"Dennis Dong Hwan Kim , Daniela Zackova , Massimo Breccia , Fabian Lang , Emiko Sakaida , Qian Jiang , Raquel De Paz , Bingcheng Liu , Susanne Isfort , David Yeung , Tomoiku Takaku , Tim H. Brümmendorf","doi":"10.1016/j.blre.2026.101366","DOIUrl":"10.1016/j.blre.2026.101366","url":null,"abstract":"<div><div>Tyrosine kinase inhibitors have transformed survival in chronic-phase chronic myeloid leukemia, yet long-term treatment success increasingly depends on treatment tolerability. Despite its recognized influence on adherence and quality of life, tolerability remains poorly defined and inconsistently addressed. To characterize existing review literature, a structured PubMed search identified review articles published between October 24, 2019, and October 23, 2024. Of 771 articles screened, 30 met inclusion criteria, 14 discussed tolerability in depth, and only 2 centered it as a primary theme. Definitions varied widely with no consensus across articles. Most reviews focused on toxicity or hospitalization, with limited coverage of low-grade, persistent adverse events or patient-reported outcomes. These findings highlight the absence of a unified understanding and prioritization of tolerability in the literature and underscore the need for a dedicated framework that clearly defines tolerability, distinguishes it from “lack of toxicity”, and incorporates patient perspectives to better guide long-term CML care.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101366"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phenocopies in acute lymphoblastic leukemia: Redefining leukemia subtypes in the transcriptomic era 急性淋巴细胞白血病的表型：在转录组学时代重新定义白血病亚型。

IF 5.7 2区医学

Blood Reviews Pub Date : 2026-04-01 Epub Date: 2026-03-04 DOI: 10.1016/j.blre.2026.101383

José Vicente Gil , Carolina Fuentes , Miguel Ángel Verde , Alberto Miralles , Sandra de las Heras , José María Fernández , Eva Barragán , Marta Llop

{"title":"Phenocopies in acute lymphoblastic leukemia: Redefining leukemia subtypes in the transcriptomic era","authors":"José Vicente Gil , Carolina Fuentes , Miguel Ángel Verde , Alberto Miralles , Sandra de las Heras , José María Fernández , Eva Barragán , Marta Llop","doi":"10.1016/j.blre.2026.101383","DOIUrl":"10.1016/j.blre.2026.101383","url":null,"abstract":"<div><div>Phenocopies are leukemias that mirror the transcriptional programs, signaling dependencies and often the clinical behavior of established genetic entities, yet lack their defining lesions. In acute lymphoblastic leukemia (ALL), RNA sequencing (RNAseq) classifiers identify phenocopy subtypes including <em>BCR::ABL1</em>-like, <em>ETV6::RUNX1</em>-like, <em>ZNF384</em>-rearranged–like and <em>KMT2A</em>-rearranged–like, which reproduce canonical expression patterns and may share drug vulnerabilities. Their emergence is reshaping taxonomy, but World Health Organization and International Consensus Classifications differ on which phenocopies merit entity status. Phenocopies can refine risk stratification within “B-other” ALL by integrating expression with genotype, copy-number alterations and measurable residual disease assessment. It may also broaden access to pathway-directed therapies (ABL, JAK–STAT, menin) for patients without sentinel fusions but with convergent circuitry. Adoption remains constrained by RNAseq availability, expertise and lesion-centric regulation. Prospective studies are needed to establish the clinical utility of newly described phenocopies, extending the advances made in subclassification and targeted treatment of <em>BCR::ABL1</em>-like ALL.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"76 ","pages":"Article 101383"},"PeriodicalIF":5.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0